NCT06686576View on ClinicalTrials.gov

A Study of Perioperative QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Colon Cancer
Interventions
BIOLOGICAL

QL1706

Phase Ib/Ⅲ： QL1706 will be administered

DRUG

CAPEOX

Phase Ⅲ：CAPEOX will be administered

Trial Locations (1)

Unknown

RECRUITING

Affiliated Cancer Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY